DSIP and sleep–wake behaviour in chronic insomnia · 1987
A small placebo-controlled, double-blind study reported improvements in sleep recordings and daytime performance. Its size and short duration limit the conclusions.
Read studyGX BIO LABS · Product artwork
Neuroscience & Peptide Signalling
DSIP
Delta-sleep-inducing peptide has been examined in small historical studies of sleep recordings and daytime function, with inconsistent findings.
Select strength
10 mg
₹3,0001 vial
Not currently available
View COA for 10 mg1 batch report available
Laboratory research only
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
Batch documentation
1 report is available for this strength. Match the batch number on your supplied material.
View available COAsUNDERSTAND THE COMPOUND
What is DSIP?
DSIP takes its name from delta-sleep-inducing peptide. Human research includes small, short studies in participants with chronic insomnia that measured sleep architecture, perceived sleep quality and daytime performance. A 1987 placebo-controlled study of 14 participants reported improvements in sleep and daytime measures. A separate 1992 double-blind study of 16 participants found some changes in objective sleep measures, but the effects were weak and subjective sleep quality did not improve. The later authors concluded that short-term treatment was unlikely to offer major therapeutic benefit. These studies do not establish a reliable insomnia treatment.
Research context
- Objective sleep recordings
- Subjective sleep quality
- Daytime alertness measures
EXPLORE THE EVIDENCE
Studies & research references
Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
DSIP in chronic insomnia: a double-blind study · 1992
Some objective sleep measures changed, but effects were weak and subjective sleep quality did not improve. The authors found little support for major short-term therapeutic benefit.
Read studyDocumentation & selection
Which strengths are listed for DSIP?
DSIP is currently listed in 10 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
Is a COA available for DSIP?
1 laboratory report is published for this compound. Match the selected strength and available batch identifiers, and open the original document to check the actual test scope.
What does this listing verify?
A catalogue listing is not a laboratory measurement. Check original documentation for the selected strength and batch before relying on identity, purity or quantity information.
CONTINUE EXPLORING
Related compounds
Neuroscience & Peptide Signalling
SemaxA synthetic seven-amino-acid peptide studied in rat neurotrophin signalling and peptide-binding experiments.
10 mg
₹2,8001 vial
Neuroscience & Peptide Signalling
SelankA synthetic tuftsin-related peptide investigated in laboratory studies of GABA-associated gene expression.
10 mg
₹2,8501 vial
Neuroscience & Peptide Signalling
PT-141PT-141, also known as bremelanotide, is a melanocortin-receptor agonist studied in defined clinical populations with sexual dysfunction.
10 mg
₹2,2501 vial
Neuroscience & Peptide Signalling
PinealonA synthetic tripeptide investigated in cell models of oxidative stress, viability and proliferation.
10 mg
₹4,3001 vial